Regulating the Pharmaceutical Industry: An Analysis of the Drug Regulatory Authority of Pakistan (DRAP)

Mehmood, Shahid (2022): Regulating the Pharmaceutical Industry: An Analysis of the Drug Regulatory Authority of Pakistan (DRAP). Published in:

Abstract

Healthy lives and the longevity of humans over time have critically been dependent upon the availability of quality drugs. Therefore, regulating the pharmaceutical industry for ensuring quality drugs and quality services (like drug dispensing) have traditionally been a priority for governments all around the globe. Pakistan is no exception, and at present has DRAP as its regulator of the pharmaceutical industry. Founded in 2012, few studies have analysed the performance of DRAP to date, and even those are limited in content, coverage and data. In sum aggregate, DRAPs performance is better than its predecessor, but there are still significant gaps to be filled and significant challenges to be addressed.

• Item Type: MPRA Paper
• English Title: Same as above
• Language: English
• Keywords: Pakistan Pharmaceutical Industry, Pharmaceutical Regulation, Regulation, DRAP, Pakistan, Medicines
• Subjects: I - Health, Education, and Welfare > I1 - Health > I18 - Government Policy ; Regulation ; Public Health; I - Health, Education, and Welfare > I3 - Welfare, Well-Being, and Poverty; I - Health, Education, and Welfare > I3 - Welfare, Well-Being, and Poverty > I38 - Government Policy ; Provision and Effects of Welfare Programs

References

‘89 medicines banned’. DAWN, 9th March 2017

‘95 percent pharmacies in Pakistan are run without a pharmacist’. Gulf News, 5th May2019

Ali, Tahir & Anum, Mujeeb (2020). Role of external factors on export potential of Pakistan pharmaceutical. Karachi University Business School

Amin, Fatima Mahmood, Khwaja Tahir Tahir, & Minaa Ul Haq, Ikram (2011). Pharmacovigilance—Need for best patient care in Pakistan: A review. Journal of Pharmaceutical Science and Research

Atif, Muhammad & Malik, Iram (2020). COVID-19 and community pharmacy services in Pakistan: Challenges, barriers and solution for progress. Journal of Pharmaceutical Policy and Practice Research

Baber, Zaheeruddin Hassali, & Mohammad Ibrahim, Mohammaed (2011). Pharmaceutical industry, innovation and challenges for public health: Case studies from Malaysia and Pakistan. Journal of Pharmaceutical Health Services and Research

Baber, Zaheeruddin Hussain, & Azhar Mohammaed, Ibrahim (2011). Compliance with legal requirements at community pharmacies: A cross sectional study from Pakistan. International Journal of Pharmacy Practice

Babar, Ayesha, Khan, Babar, Godman, Brian, Hussain, Shahzad, Mahmood, Sidra, & Aqeel, Tahir (2016). Assessment of active pharmaceutical ingredients in drug registration procedures in Pakistan: implications for the future. Generics and Biosimilars Initiative journal, 5(4), 156–163

Bigdeli M, Rashidian, A., & Stephens, P. N. (2017). Essential medicines for universal health coverage. Lancet, 403–76. Bringing hope to sufferers of a neglected disease (2018). Medicines Sans Frontier (MSF)

Dattaa, Biplab K., Husain, Muhammad J., & Fatehin, Sohani (2020). The crowding out effect of out-of-pocket medication expenses of two major non-communicable diseases in Pakistan. International Health, 12(1)

Hafeez, A., Kiani, A. G., Din, S., & Muhammad, W. (2004). Prescription and dispensing practices in public sector health facilities in Pakistan: Survey report. Journal of Pakistan Medical Association

Hasan, Khaqan S. (2012). Prospects of drug bioequivalence studies in Pakistan. Journal of the Dow University Health Sciences

Hashmi, Furqan, Hussain, Rabia Rehman, & Anees Ur (2020). Physicians understanding and practices of pharmacovigilance: Qualitative experience from a lower middle income country. Journal of Pharmaceutical Policy and Practice. 42

Hussain, Rabia & Hassali, Mohammed Azmi (2019). Current status and future prospects of pharmacovigilance in Pakistan. Journal of Pharmaceutical Policy and Practice Research.

Junaidi, I. (2013). Prices of pharmaceuticals likely to increase. Dawn, 19th June 2013.

Junaidi, I. (2013). Medicines being sold in black market. Dawn, 21st November 2013.

Khan, Muhammed Mushtaq (2006). Health policy analysis—The case of Pakistan. University of Groningen.

Mehmood, Shahid (2021). Economics of vaccines. DAWN, 28th March 2021.

Operations against spurious medicines in Pindi (2021). Business Recorder, 21st June.

Pakistani drug regulatory body a complete failure (2017). Pharma File

Blackstone, Erwin A., Pociask, Steve, & Fuhr, Joseph (2014). The health and economic effects of counterfeit drugs. American Health and Drug Benefits.

Pharmaceutical Country Profile- Pakistan (2010). World Health Organisation (WHO).

Planning Commission Milestone 6—Launching Implementation (2010). Planning Commission.

Price hike: legislators call for action against pharma companies (2016). Express Tribune, 20th February.

Rashid, Hira (2015). Impact of the drug regulatory authority, Pakistan: An evaluation. New Visions for Public Affairs, 7.

Shaheen, Sardar Sikander (2020). Minister explains why prices of medicines increased. Business Recorder, 24th October 2020.

Zaidi, Shehla, Bigdeli, Maryam, Allem, Noureen, & Rashidian, Arash (2013). Access to essential medicines in Pakistan: Policy and health systems research concerns. Agha Khan University, Karachi.